For people with allergies, ongoing exposure to triggers may create a cycle of inflammation that contributes to polyp ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...

The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total Nasal ... name Tezspire ® for the add-on maintenance treatment of severe asthma in adult and ...

Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

Researchers recently identified five extrapulmonary treatable traits in asthma that are clinically relevant and have a clear diagnostic process.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...